YARROW BIOSCIENCE, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
YARROW BIOSCIENCE, INC. (YARW) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-06.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2025-03-06
- YARROW BIOSCIENCE, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2021-12-31 was $0.00, a 100.00% decline year-over-year.
- YARROW BIOSCIENCE, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2021-09-30 was $0.00.
- YARROW BIOSCIENCE, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2021-06-30 was $0.00, a 100.00% decline year-over-year.
- YARROW BIOSCIENCE, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2021-03-31 was $0.00, a 100.00% decline year-over-year.
- YARROW BIOSCIENCE, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- YARROW BIOSCIENCE, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $207.00K.
- YARROW BIOSCIENCE, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $0.00.
- YARROW BIOSCIENCE, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-03-06 | |||
| 2023-12-31 | $207.00K 10-K · filed 2025-03-06 | |||
| 2022-12-31 | $0.00 10-K · filed 2024-03-01 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $0.00 derived: sum of 2 quarters · filed 2022-03-17 | $0.00 derived: sum of 3 quarters · filed 2022-03-17 | $0.00 10-K · filed 2022-03-17 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $0.00 derived: sum of 2 quarters · filed 2021-11-10 | $0.00 10-Q · filed 2021-11-10 | $230.00K derived: sum of 4 quarters · filed 2022-03-17 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $0.00 10-Q · filed 2021-08-12 | $230.00K derived: sum of 3 quarters · filed 2022-03-17 | $230.00K derived: sum of 4 quarters · filed 2022-03-17 |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-06 | $230.00K derived: sum of 2 quarters · filed 2022-03-17 | $230.00K derived: sum of 3 quarters · filed 2022-03-17 | $1.06M derived: sum of 4 quarters · filed 2022-03-17 |
| 2020-12-31 | $230.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $230.00K derived: sum of 2 quarters · filed 2022-03-17 | $1.06M derived: sum of 3 quarters · filed 2022-03-17 | $1.35M 10-K · filed 2022-03-17 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $833.00K derived: sum of 2 quarters · filed 2021-11-10 | $1.12M 10-Q · filed 2021-11-10 | $1.10M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $833.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $1.12M 10-Q · filed 2021-08-12 | $1.10M derived: sum of 3 quarters · filed 2021-08-12 | $1.43M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $287.00K 10-Q · filed 2021-05-06 | $269.00K derived: sum of 2 quarters · filed 2021-05-06 | $595.00K derived: sum of 3 quarters · filed 2021-05-06 | $726.00K derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | -$18.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | $308.00K derived: sum of 2 quarters · filed 2021-03-04 | $439.00K derived: sum of 3 quarters · filed 2021-03-04 | $1.18M 10-K · filed 2021-03-04 |
| 2019-09-30 | $326.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $457.00K derived: sum of 2 quarters · filed 2020-11-05 | $1.19M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $131.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $867.00K 10-Q · filed 2020-08-06 | ||
| 2019-03-31 | $736.00K 10-Q · filed 2020-05-11 | |||
| 2018-12-31 | $0.00 10-K · filed 2021-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B |